CD274 and cancer: Antibody‐based drugs such as nivolumab or atezolizumab have been developed to block the interaction of PD‐L1 and PD‐1 with the intention of recovering the function of CTLs, and these efforts have led to great success with multiple cancer treatments.8, 9